Jakura 5mg (Tofacitinib 5mg)

Jakura 5mg, which is also known as Tofacitinib 5mg, is a generic inhibitor of Janus kinases (JAKs). It has received approval for the treatment of various medical conditions, such as:

• Moderately to severely active rheumatoid arthritis in adult patients who have not responded well to methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs). Jaknat 5mg can be used alone or in combination with methotrexate or other non-biologic DMARDs. However, it is not recommended to be used together with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.

• Active psoriatic arthritis in adult patients who have not responded well to methotrexate or other DMARDs. Similar to its use in rheumatoid arthritis, Jaknat 5mg can be used alone or in combination with other non-biologic DMARDs, but not with biologic DMARDs or potent immunosuppressants like azathioprine and cyclosporine.

• Moderately to severely active ulcerative colitis (UC) in adult patients who have not responded well to TNF blockers or are intolerant to them. However, using Jaknat 5mg in combination with biologic therapies for UC or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

• Active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients aged two years and older. Tofacitinib's oral solution is indicated for this use. However, it should not be used together with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.

Tofacitinib DOSAGE

To treat Rheumatoid Arthritis, Tofacitinib is usually prescribed at a dose of 5 mg twice daily or 11 mg once daily. However, in patients with moderate to severe renal impairment or moderate hepatic impairment, the recommended dose is 5 mg once daily. Tofacitinib 11mg is not recommended for patients with severe hepatic impairment. Additionally, studies suggest that turmeric supplements may help relieve arthritis and joint pain.

For Psoriatic Arthritis, the recommended dose of Tofacitinib is 5 mg twice daily in combination with nonbiologic DMARDs or 11 mg once daily in combination with nonbiologic DMARDs. The recommended dose for patients with moderate to severe renal impairment or moderate hepatic impairment is 5 mg once daily. Tofacitinib 11mg is not recommended for patients with severe hepatic impairment.

To treat Ulcerative Colitis, Tofacitinib is usually prescribed at a dose of 10 mg twice daily or 22 mg once daily for 8 weeks for induction. After 8 weeks, patients should be evaluated and transitioned to maintenance therapy based on their therapeutic response. For maintenance therapy, the recommended dose is 5 mg twice daily or 11 mg once daily. Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment.

For Polyarticular Course Juvenile Idiopathic Arthritis, the recommended dose of Tofacitinib Oral Solution is 5 mg twice daily or weight-based equivalent twice daily. Dosage adjustment is also needed in patients with moderate and severe renal impairment or moderate hepatic impairment. For more details, please refer to the full prescribing information.

Tofacitinib Side Effects：

TOFACITINIB 5MG/11MG is an immune system affecting medication that can lower your body's ability to fight infections, which may include severe infections like tuberculosis, bacterial, fungal, or viral infections that can spread throughout the body. In some cases, such infections have been fatal. Before starting and during treatment with TOFACITINIB 5MG/11MG, your healthcare provider should test you for tuberculosis and closely monitor you for signs of infection.

If you currently have an infection, unless your healthcare provider says it's safe to do so, you should not take TOFACITINIB 5MG/11MG. Inform your healthcare provider about any history of infections, chronic lung disease, diabetes, HIV, weak immune system, or if you live in or have traveled to areas where fungal infections are common. If you experience any symptoms of infection such as fever, cough, or diarrhea, contact your healthcare provider immediately.

Taking TOFACITINIB 5MG/11MG can increase the risk of certain types of cancer, such as lymphoma and skin cancer. You should inform your healthcare provider if you have a history of cancer. Moreover, combining TOFACITINIB with certain other medicines has caused uncontrolled growth of white blood cells in some individuals.

Taking TOFACITINIB 5MG/11MG can also increase the risk of tears in the stomach or intestines, especially when taken with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. If you have a history of diverticulitis or ulcers in your stomach or intestines, inform your healthcare provider. If you experience fever and persistent stomach-area pain, or a change in bowel habits, seek medical attention right away.

While taking TOFACITINIB 5MG/11MG, your healthcare provider should regularly check certain blood tests such as lymphocyte, neutrophil, and red blood cell counts, as well as liver tests. If any of these tests yield abnormal results, your healthcare provider may temporarily halt treatment. Your blood cholesterol levels should also be monitored regularly as normal cholesterol levels are important for good heart health.

Tofacitinib generic India：

Purchasing Tofacitinib online from an Indian pharmacy is only 8% of the cost of the brand-name Tofacitinib..

Tofacitinib PI

For more information on prescribing, please contact our customer service to request the "FDA Prescribing Information."